Tender detail
Non-exclusive discount agreements for subcutaneous infliximab under an open-house model
Summary
The procurement covers non-exclusive discount agreements under an open-house model for medicines containing infliximab for subcutaneous injection (ATC code L04AB02). Quantities depend on actual demand, and no minimum purchase quantities are guaranteed. The agreements end no later than 30 June 2028.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.